New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
06:27 EDTMNTA
theflyonthewall.com: Momenta Pharma upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded Momenta Pharmaceuticals as it finds the stock attractive ahead of FDA's decision on M-enoxaparin. The firm has a $15 price target on the stock. :theflyonthewall.com



News For MNTA From The Last 14 Days
Check below for free stories on MNTA the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2010
10:34 EDTMNTA
theflyonthewall.com: FDA rejects conflict of interest claim involving Momenta Pharma, LA Times says

Subscribe for More Information
:theflyonthewall.com
10:25 EDTMNTA
theflyonthewall.com: Momenta Pharma mentioned positively at Rodman & Renshaw
Rodman & Renshaw said the FDA investigation finds no conflict of interest in research during the 2008 heparin crisis, a time when the firm had a drug application pending. :theflyonthewall.com